Zastosowanie mikropęcherzyków (MV) pochodzących z komórek macierzystych do wytwarzania leku do regeneracji śródbłonkowej/nabłonkowej uszkodzonych lub poddanych urazowi tkanek lub narządów i związane z nimi sposoby in vitro i in vivo农业专利-农业学术服务平台

摘要：: The invention relates to the use of microvesicles (MVs) derived from stem cells for preparing a medicament for the endo/epithelial regeneration of damaged tissues or organs and/or for inhibiting the apoptosis induced by cytostatic agents. The stem cell from which the microvesicles are obtained is preferably selected from the group consisting of endothelial progenitor cells (EPCs), mesenchimal stem cells (MSCs), renal progenitors CD133+, adult human liver stem cells (HLSC) and any combination thereof. The microvesicles may be used in both in vitro and in vivo applications, such as for example the regeneration of damaged tissues or organs and the treatment of renal injury and hepatic injury, particularly acute renal failure (ARF) and acute hepatic failure (AHF).